Gene · 10666
Papers4,079
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 4,079
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Non-HLA risk variants in a type 1 diabetes pediatric population: Clinical and autoimmune profiles. | An Pediatr (Engl Ed) | 2026 | 41521103 | PubTator, text mining | PubMed |
| Immune checkpoint remodeling across disease progression in multiple myeloma. | Neoplasma | 2026 | 41410506 | PubTator, text mining | PubMed |
| Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8+ T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients. | Transplant Cell Ther | 2026 | 41325869 | PubTator, text mining | PubMed |
| Elevated CD39 + T Cells Contribute to Immune Regulatory Imbalance in Systemic Lupus Erythematosus. | Immunology | 2026 | 41221548 | PubTator, text mining | PubMed |
| CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss. | J Immunol | 2026 | 41186276 | PubTator, text mining | PubMed |
| Novel Multi-Biomarker Nomogram Combining CD155/CD226/TIGIT/CD96 Immune Checkpoint Axis for Postoperative Survival Prediction in Breast Cancer. | Clin Breast Cancer | 2026 | 41073220 | PubTator, text mining | PubMed |
| Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' Disease | Endocr Metab Immune Disord Drug Targets | 2026 | 39945256 | PubTator, text mining | PubMed |
| Targeting Impaired Type I Interferon-IL-27 Signaling Rescues T Regulatory Cell Suppressive Function in Relapsing-Remitting Multiple Sclerosis. | bioRxiv | 2025 | 41783369 | PubTator, text mining | PubMed |
| Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. | Front Immunol | 2025 | 41613119 | PubTator, text mining | PubMed |
| Progenitor-predominant exhaustion in cytokine-induced killers reveals TIM-3 as a superior target for enhancing cytokine-induced killer cytotoxicity. | J Leukoc Biol | 2025 | 41414757 | PubTator, text mining | PubMed |
| Cost-effective non-additive GWAS across 2329 diseases in 500,349 individuals. | Nat Commun | 2025 | 41390737 | PubTator, text mining | PubMed |
| HLA class-I genotyping to personalize Bacille Calmette-Guerin immunotherapy in bladder cancer. | Oncoimmunology | 2025 | 41384865 | PubTator, text mining | PubMed |
| Post-radiation targeting of TIGIT and CD96 improved immunotherapy efficacy in head and neck squamous cell carcinoma. | Mol Med | 2025 | 41382272 | PubTator, text mining | PubMed |
| Molecular analysis of immune cell subsets and cytokine profiles in septic Vietnamese patients. | Clin Exp Med | 2025 | 41348239 | PubTator, text mining | PubMed |
| MicroRNA-mediated regulation of natural killer cells development, effector functions, and antitumor responses. | Cancer Cell Int | 2025 | 41331607 | PubTator, text mining | PubMed |
| Immunotherapeutic strategies targeting the PVR-TIGIT/CD96/CD226 signaling pathway in glioma treatment. | Ann Med | 2025 | 41254994 | PubTator, text mining | PubMed |
| Integrated bulk and single-cell transcriptomic profiling reveals NECTIN-TIGIT interaction underlies T cell exhaustion in papillary thyroid carcinoma. | Clin Exp Med | 2025 | 41249602 | PubTator, text mining | PubMed |
| Predictive value of NKG2A+ NK cell population in diagnosing severe COVID-19 patients. | Immunobiology | 2025 | 41218237 | PubTator, text mining | PubMed |
| CD155-TIGIT/CD96/CD226 immune checkpoint axis interacting with tumor-infiltrating lymphocytes to exhibit diverse prognostic effects on breast cancer: a cohort study. | Front Immunol | 2025 | 41181119 | PubTator, text mining | PubMed |
| The predictive effect of the CD155-TIGIT immune checkpoint axis complex on neoadjuvant chemotherapy efficacy in triple-negative breast cancer: A preliminary study. | Cancer Biomark | 2025 | 41134836 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10666/papers?page=6